Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network

PLoS Medicine(2020)10.1371/journal.pmed.1003393Source: DataRank Database

The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network is a research paper published in PLoS Medicine (2020). On theSindex it has a DataRank of 0. It has been cited 64 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access64 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 2.68)OA: goldTopics (37)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (48)

Robert J. Commons ORCID,Nicola Davies ORCID,Kamala Thriemer ORCID,Bereket Hailegiorgis Alemayehu,Chanaki Amaratunga

Live enrichment

PubMed:33211712 PMC:PMC7676739 OpenAlex:https://openalex.org/W3106462464

Wellcome Trust

Grant: 200909

National Health and Medical Research Council

Grant: 1104975

Bill and Melinda Gates Foundation

Grant: 1054404

National Health and Medical Research Council

Grant: 1334989

Wellcome Trust

Grant: 200909/Z/16/Z

Wellcome Trust

Grant: 214208/Z/18/Z

Gates Foundation

Grant: INV-007122

Medical Research Council

Grant: MC_UP_A900_1119

Bill and Melinda Gates Foundation

National Health and Medical Research Council

FWCI

2.68

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003393&type=printable

publisherhttps://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1003393&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pmed.1003393

journalhttps://doi.org/10.1371/journal.pmed.1003393

repositoryhttps://research-repository.uwa.edu.au/en/publications/3e5794be-8bba-421a-8f1f-2891c2284547

Fields of Study

Malaria Research and ControlVector-borne infectious diseasesParasites and Host Interactions

MeSH Terms

Artemether, Lumefantrine Drug CombinationAdolescentAdultAgedAged, 80 and overAntimalarialsChildChild, PreschoolFemaleHumansInfantMalariaMaleMiddle AgedPlasmodium vivaxMalaria, FalciparumMalaria, VivaxParasitemiaArtemisininsYoung Adult

Keywords

MedicineArtemether/lumefantrineAmodiaquineArtesunatePlasmodium vivaxMalariaInterquartile rangeInternal medicineMeta-analysisArtemetherPlasmodium falciparumCohort studyArtemisininImmunology

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis

10.6084/m9.figshare.14677012.v1figshare

Additional file 1 of The high risk of malarial recurrence in patients with Plasmodium-mixed infection after treatment with antimalarial drugs: a systematic review and meta-analysis

10.6084/m9.figshare.14677012figshare

Additional file 1 of Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

10.6084/m9.figshare.19793505.v1figshare

Additional file 1 of Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

10.6084/m9.figshare.19793505figshare

Additional file 2 of Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

10.6084/m9.figshare.19793508figshare

Additional file 2 of Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

10.6084/m9.figshare.19793508.v1figshare

Additional file 3 of Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

10.6084/m9.figshare.19793511.v1figshare

Additional file 3 of Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas—a randomized controlled trial (PRIMA)

10.6084/m9.figshare.19793511figshare

Additional file 1 of Spatio-temporal trends of malaria incidence from 2011 to 2017 and environmental predictors of malaria transmission in Myanmar

10.6084/m9.figshare.26564691.v1figshare

Additional file 1 of Spatio-temporal trends of malaria incidence from 2011 to 2017 and environmental predictors of malaria transmission in Myanmar

10.6084/m9.figshare.26564691figshare